ADCT
ADC Therapeutics SA
NYSE · Healthcare · Biotechnology · CH
$1.05
−0.94%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$0.21
- Revenue estimate
- $18.4M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.22
- Revenue actual
- $19.2M
- Revenue estimate
- $18.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +21.2%
- Revenue beats (12Q)
- 9
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.22 | -$0.11 | Beat 49.07% | $19.2M |
| May 4, 2026 | -$0.19 | -$0.21 | Miss -10.53% | $20.9M |
| Mar 10, 2026 | -$0.27 | -$0.04 | Beat 85.09% | $23.1M |
| Aug 12, 2025 | -$0.36 | -$0.50 | Miss -38.89% | $18.8M |
| May 14, 2025 | -$0.38 | -$0.36 | Beat 5.26% | $23.0M |
| Mar 27, 2025 | -$0.35 | -$0.29 | Beat 17.14% | $16.9M |
| Nov 7, 2024 | -$0.36 | -$0.42 | Miss -16.67% | $18.5M |
| Mar 13, 2024 | -$0.47 | -$1.03 | Miss -119.15% | $16.8M |
| Feb 28, 2023 | -$0.49 | -$0.30 | Beat 38.78% | $69.8M |
| Mar 3, 2022 | -$0.87 | -$0.39 | Beat 55.17% | $17.0M |
| Nov 2, 2021 | -$0.97 | -$0.59 | Beat 39.18% | $13.1M |
| May 6, 2021 | -$1.00 | -$0.74 | Beat 26.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026